IMR Press / FBL / Special Issues / 1419577676972609537

Application of novel diagnosis and treatment technologies in precision oncology

Submission deadline: 31 December 2023
Special Issue Editors
Xiaofang Che
Department of Oncology Medical, The First Hospital of China Medical University
Interests: To Screen the Predictors of Prognosis and Efficacy and to Establish the Predictive Models Based on Tumor Microenvironment; To Explore the New Therapy Strategy and the Resistance Reversal Strategy for Refractory Cancer
Jia Wang
Department of Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
Interests: Breast Cancer; Molecular Pathogenesis; AI-based Cancer Diagnosis and Treatment
Chunlei Zheng
Department of Oncology Medical, Shanghai Electric Power Hospital
Interests: To Explore the Effects and the Underlying Mechanism of Epigenetic and Metabolic Changes on the Prognosis of Various Cancers; such as Lung Cancer, Breast Cancer and Gastrointestinal Cancer
Special Issue Information

Dear Colleagues,

Much progress has been made in comprehensive strategy for cancer therapy including surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy, has significantly improved the prognosis of patients with malignant tumors. However, due to the difficulty of early diagnosis, strong spatial-temporal heterogeneity, limited curative effect and the occurrence of resistance, the incidence and mortality of cancers still remains high. Therefore, to prolong the overall survival and to avoid the overtreatment or insufficient treatment, it is of great significance to make the right diagnose and the reasonable individualized treatment plan for cancer patients, the so-called precision oncology. The rapid development of bioinformatics analysis and next generation sequencing (NGS) has promoted the progress of precision oncology, in which the representative example is that EGFR mutation detection has been widely used for the guidance of EGFR-TKI therapy in lung cancer. Precision oncology is needed throughout the whole process from diagnosis to therapy, including the precise prediction of risk, diagnosis, classification and prognosis, as well as the precise screening of superior therapeutic population, assessment of efficacy and the development of new drugs. In recent years, more and more novel technologies have been developed explosively, including proteomics, metabolomics, intestinal microbiome, single cell sequencing, spatial transcriptome, liquid biopsy, molecular imaging, artificial intelligence, molecular docking, etc. In particular, because of multiple merits including its non-invasive or minimally invasive, easy to obtain specimens, easy to collect images, easy to be accepted by patients, liquid biopsy technology based on ctDNA/CTC/exosome, and radiomics technology based on CT/MRI/ultrasonic, have attracted much attention in early diagnosis, prognosis prediction, efficacy prediction, dynamic monitoring and so on. Moreover, due to the spatial-temporal heterogeneity, the existing treatment methods could not be effective for all cancer patients. Therefore, how to screen the treatment sensitive population and explore new drugs or drug resistance reversal strategies for insensitive patients is also an important challenge of precision oncology.

In this Special Issue, we aim to collect Original Research and Review articles focusing on novel technologies related to cancer diagnosis, prognostic prediction, efficacy prediction and the exploration of new drugs or resistance reversal strategies as described above. We hope this Special Issue will lead to a better understanding of precision cancer medicine, provide useful technologies for clinical application and highlight the clinical significance. In silico data analysis needs to be verified with in vitro/in vivo experiment.

Prof. Xiaofang Che, Assoc. Prof. Jia Wang and Assoc. Prof. Chunlei Zheng

Guest Editors

Keywords
Cancer
Precision Medicine
Biomarker
Artificial Intelligence (AI)
Liquid Biopsy
New Therapy Strategy
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Back to top